International Journal of Catalysis and Chemical Engineering
Synthesis, Characterization and Evaluation of NiFe2O4/Cr2O3 Nano Composite as T1-T2 Contrast Agents for High-Field MRI
Abstract
Hamza Khalid and Akbar Ali
Synthesis, Characterization and Evaluation of NiFe2 O4 /Cr2 O3 Nano composites as promising class of T1-T2 contrast agents for high-field MRI Compared to conventional contrast agents like gadoliniumbased chelates, this composite possesses several benefits, such as improved biocompatibility, lower toxicity, and increased relativity In current study, we used a straightforward hydrothermal process to synthesis NiFe2 O4 /Cr2 O3 nanocomposites, and X-ray diffraction, and scanning electron microscopy were among the methods we employed to describe them. They were also evaluated for their effectiveness as T1-T2 contrast agents in vivo and in vitro. NiFe2 O4 /Cr2 O3 nanocomposites have low toxicity and great relaxivity, according to the results. The nanocomposites could considerably improve the contrast of MRI images in both the T1 and T2 weighted modes, according to in vivo investigations. The NiFe2 O4 /Cr2 O3 NCPs ‘ T1 and T2 relaxivities were tested at 3 T and 7 T. The T1 and T2 relaxivities of the nanocomposites rose as the Cr2 O3 content increased, according to the results. The NiFe2O4/Cr2 O3 nanocomposites with a 50% Cr2 O3 concentration had the maximum T1 relaxivity of 22.5 mM-1 s-1 and T2 relaxivity of 52.8 mM-1 s-1.Overall, these findings point to NiFe2 O4 /Cr2 O3 nanocomposites as a potential T1-T2 high-field magnetic resonance imaging contrast agent. They may enhance the identification and tracking of numerous illnesses, including stroke and cancer. For high-field MRI, NiFe2 O4 /Cr2 O3 NCPs are very effective T1- T2 contrast agents. Our approach is easy to use, scalable, and reasonably priced. The NCPs can dramatically improve the contrast of MRI images in both T1 and T2 weighted modes in vivo. They also have a high relaxivity and low toxicity. Our NCPs are distinct in various aspects. Initially, they consist of two distinct spinel ferrite oxides, NiFe2 O4 and Cr2 O3 , which work in concert to enhance relaxivity. Second, the NCPs consist of a NiFe2 O4 core and a Cr2 O3 shell, forming a core- shell structure. The NCPs ‘ T2 relaxivity is improved by this structure. Third, the NCPs are suited for in vivo applications because they are covered with a biocompatible layer of polyethylene glycol (PEG). Our nanocomposites may help with the detection and tracking of numerous illnesses, including stroke and cancer. Our NCPs, for instance, could be applied to the assessment of stroke damage or the detection and tracking of brain tumor development. Our nanocomposites have the potential to be employed for therapeutic applications in addition to diagnostic ones. Our nanocomposites could be applied, for instance, to enhance tissue regeneration following a stroke or to deliver therapeutic medications to Cancers. In general, our novel class of T1-T2 contrast agents for high-field MRI using NiFe2 O4 /Cr2 O3 NCPs shows promise. They may enhance the identification, management, and observation of numerous illnesses. The cytotoxicity and in vivo magnetic resonance imaging performance of the NiFe2 O4 /Cr2 O3 nanocomposites were also assessed. The human embryonic kidney (HEK293) cells were not harmed by the nanocomposites, according to the cytotoxicity data. The T1 and T2 contrast of mice livers may be markedly improved by the NiFe2 O3 /Cr2 O3 NCPs, according to the in vivo MRI results.